Van ECK Associates Corp Increases Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Van ECK Associates Corp lifted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 34.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,260 shares of the company's stock after purchasing an additional 7,027 shares during the quarter. Van ECK Associates Corp owned about 0.09% of Medpace worth $9,057,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. State Street Corp boosted its position in shares of Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company's stock worth $251,337,000 after purchasing an additional 50,312 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Medpace by 7.6% in the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock worth $209,885,000 after purchasing an additional 44,371 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. American Capital Management Inc. lifted its position in Medpace by 2.6% during the 3rd quarter. American Capital Management Inc. now owns 380,646 shares of the company's stock worth $127,060,000 after acquiring an additional 9,592 shares during the period. Finally, FMR LLC lifted its position in Medpace by 11.8% during the 3rd quarter. FMR LLC now owns 231,019 shares of the company's stock worth $77,114,000 after acquiring an additional 24,362 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research reports. TD Cowen lowered their price target on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research report on Wednesday, October 23rd. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Finally, Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $381.44.

Medpace Trading Up 0.3 %

NASDAQ:MEDP traded up $0.89 during trading hours on Thursday, hitting $344.85. The company's stock had a trading volume of 258,159 shares, compared to its average volume of 276,253. The stock has a market capitalization of $10.51 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 3.77 and a beta of 1.36. The stock has a fifty day moving average of $343.28 and a 200-day moving average of $347.47. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.